Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With Relapsed AML

Trial Profile

Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With Relapsed AML

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs JTCR 016 (Primary) ; Aldesleukin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jul 2017 Patients with myelodysplastic syndromes and acute-myeloid-leukaemia will no longer be considered eligible for the study.
    • 13 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2017.
    • 18 Mar 2015 According to a Juno Therapeutics media release, data from this trial has been presented at the 56th annual American Society of Hematology (ASH) meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top